Targeting Nr4a1 to help treat cocaine addiction.
Advancing Nr4a1 as a novel target in cocaine use disorder.
This study is exploring a new way to help people with cocaine addiction by looking at a protein that might help reduce cravings, and they’re working on a treatment using a natural compound that activates this protein.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rafias LLC NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11032992 on NIH RePORTER |
What this research studies
This research investigates a new approach to treating cocaine use disorder by focusing on a protein called Nr4a1. The team has found that activating Nr4a1 can reduce cocaine-seeking behavior in mice, suggesting it could be a promising target for new therapies. They plan to develop a treatment using a natural compound that activates Nr4a1, potentially leading to a medication that could help individuals struggling with cocaine addiction. The research is at an early stage, aiming to identify and develop effective therapies for this condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals struggling with cocaine use disorder who have not found success with existing treatment options.
Not a fit: Patients who are not affected by cocaine addiction or those who have severe co-occurring mental health disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of a new medication for cocaine addiction, providing an alternative to current psychosocial treatments.
How similar studies have performed: While targeting Nr4a1 is a novel approach, previous studies have shown promise in using similar methods to address addiction, indicating potential for success.
Where this research is happening
Philadelphia, United States
- Rafias LLC — Philadelphia, United States (Active)
Researchers
- Principal investigator: Heller, Elizabeth a — Rafias LLC
- Study coordinator: Heller, Elizabeth a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.